JP2025502891A5 - - Google Patents
Info
- Publication number
- JP2025502891A5 JP2025502891A5 JP2024543040A JP2024543040A JP2025502891A5 JP 2025502891 A5 JP2025502891 A5 JP 2025502891A5 JP 2024543040 A JP2024543040 A JP 2024543040A JP 2024543040 A JP2024543040 A JP 2024543040A JP 2025502891 A5 JP2025502891 A5 JP 2025502891A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263300893P | 2022-01-19 | 2022-01-19 | |
| US63/300,893 | 2022-01-19 | ||
| PCT/JP2023/001270 WO2023140269A1 (en) | 2022-01-19 | 2023-01-18 | Treatment of autoimmune encephalitis with satralizumab |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025502891A JP2025502891A (ja) | 2025-01-28 |
| JP2025502891A5 true JP2025502891A5 (https=) | 2026-01-14 |
| JPWO2023140269A5 JPWO2023140269A5 (https=) | 2026-01-14 |
Family
ID=87348849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024543040A Pending JP2025502891A (ja) | 2022-01-19 | 2023-01-18 | 自己免疫性脳炎のサトラリズマブによる治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250127891A1 (https=) |
| EP (1) | EP4466018A4 (https=) |
| JP (1) | JP2025502891A (https=) |
| KR (1) | KR20240145472A (https=) |
| CN (1) | CN118900699A (https=) |
| AU (1) | AU2023209259A1 (https=) |
| CA (1) | CA3243067A1 (https=) |
| IL (1) | IL314213A (https=) |
| MX (1) | MX2024008835A (https=) |
| TW (1) | TW202337495A (https=) |
| WO (1) | WO2023140269A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2892925T3 (es) | 2006-03-31 | 2022-02-07 | Chugai Pharmaceutical Co Ltd | Métodos para controlar la farmacocinética en sangre de anticuerpos |
| EP3620531A4 (en) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS |
| WO2019151418A1 (ja) | 2018-01-31 | 2019-08-08 | 元一 加藤 | Ｉｌ－６阻害剤を含有する喘息の治療剤 |
| IL287220B2 (en) | 2019-04-17 | 2026-03-01 | Univ Hiroshima | A therapeutic agent for urological cancer characterized by administering an IL-6 inhibitor in combination with a CCR2 inhibitor |
| AU2021278562A1 (en) | 2020-05-29 | 2022-12-01 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing formulation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2206775B1 (en) | 2007-09-26 | 2016-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-il-6 receptor antibody |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| US20120039840A1 (en) | 2008-12-02 | 2012-02-16 | Hunter Christopher A | Use of IL-27-P28 to antagonize IL-6 mediated signaling |
| JP6130983B2 (ja) | 2015-02-27 | 2017-05-17 | 中外製薬株式会社 | Ｉｌ−６関連疾患治療用組成物 |
| JPWO2020202839A1 (https=) * | 2019-03-29 | 2020-10-08 |
-
2023
- 2023-01-18 CN CN202380028068.8A patent/CN118900699A/zh active Pending
- 2023-01-18 KR KR1020247027265A patent/KR20240145472A/ko active Pending
- 2023-01-18 AU AU2023209259A patent/AU2023209259A1/en active Pending
- 2023-01-18 CA CA3243067A patent/CA3243067A1/en active Pending
- 2023-01-18 TW TW112102365A patent/TW202337495A/zh unknown
- 2023-01-18 JP JP2024543040A patent/JP2025502891A/ja active Pending
- 2023-01-18 WO PCT/JP2023/001270 patent/WO2023140269A1/en not_active Ceased
- 2023-01-18 EP EP23743263.8A patent/EP4466018A4/en active Pending
- 2023-01-18 MX MX2024008835A patent/MX2024008835A/es unknown
- 2023-01-18 IL IL314213A patent/IL314213A/en unknown
- 2023-01-18 US US18/729,273 patent/US20250127891A1/en active Pending